Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Novartis
Cerilliant
Julphar
Federal Trade Commission
US Army
Queensland Health
Boehringer Ingelheim
Colorcon

Generated: January 19, 2018

DrugPatentWatch Database Preview

Rifaximin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for rifaximin and what is the scope of rifaximin patent protection?

Rifaximin
is the generic ingredient in one branded drug marketed by Salix Pharms and is included in two NDAs. There are twenty-six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Rifaximin has two hundred and thirty-four patent family members in thirty-six countries.

There are twelve drug master file entries for rifaximin. Six suppliers are listed for this compound.
Pharmacology for rifaximin
Ingredient-typeRifamycins
Drug ClassRifamycin Antibacterial

US Patents and Regulatory Information for rifaximin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for rifaximin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,566,270 Methods for treating irritable bowel syndrome (IBS) ➤ Subscribe
7,923,553 Processes for the production of polymorphic forms of rifaximin ➤ Subscribe
7,081,239 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia ➤ Subscribe
7,056,686 Method of diagnosing fibromyalgia caused by small intestinal bacterial overgrowth ➤ Subscribe
8,562,952 Methods for manipulating satiety ➤ Subscribe
7,736,622 Methods of diagnosing small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions ➤ Subscribe
9,629,829 Methods of treating hepatic encephalopathy ➤ Subscribe
7,244,412 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia ➤ Subscribe
8,110,177 Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions ➤ Subscribe
7,608,245 Methods for manipulating satiety ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for rifaximin

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Queensland Health
Teva
Medtronic
UBS
Covington
Citi
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot